A macrophage invasion mechanism of pathogenic mycobacteria

Science

Volumn 277, Issue 5329, 1997, Pages 1091-1093

  Schorey, Jeffrey S ^a   Carroll, Michael C ^b   Brown, Eric J ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CELL INVASION; COMPLEMENT ACTIVATION; MACROPHAGE ACTIVATION; MYCOBACTERIUM; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; OPSONIZATION; PATHOGENICITY; PRIORITY JOURNAL;

AMINO ACID SEQUENCE; ANIMALS; COMPLEMENT C2; COMPLEMENT C2A; COMPLEMENT C3; COMPLEMENT C3-C5 CONVERTASES; COMPLEMENT C3B; HORSES; HUMANS; ISOFLUROPHATE; MACROPHAGES; MICE; MOLECULAR SEQUENCE DATA; MYCOBACTERIUM; MYCOBACTERIUM AVIUM COMPLEX; MYCOBACTERIUM BOVIS; MYCOBACTERIUM LEPRAE; MYCOBACTERIUM TUBERCULOSIS; OPSONIN PROTEINS; VIRULENCE;

CORYNEBACTERINEAE; MYCOBACTERIUM AVIUM; MYCOBACTERIUM LEPRAE; MYCOBACTERIUM TUBERCULOSIS;

EID: 0030777141     PISSN: 00368075     EISSN: None     Source Type: Journal    
DOI: 10.1126/science.277.5329.1091     Document Type: Article

References (36)

1. M. J. Fenton and M. W. Vermeulen, Infect. Immun. 64, 683 (1996).
2. J. C. Weissler, Am. J. Med. Sci. 305, 52 (1993).
3. J. J. Ellner, M. J. Goldberger, D. M. Parenti, J. Infect. Dis. 163, 1326 (1991).
4. L. S. Schlesinger and M. A. Horwitz, J. Immunol. 147, 1983 (1991); L. S. Schlesinger, C. G. Bellinger-Kawahara, N. R. Payne, M. A. Horwitz, ibid. 144, 277 (1990).
5. L. S. Schlesinger and M. A. Horwitz, J. Immunol. 147, 1983 (1991); L. S. Schlesinger, C. G. Bellinger-Kawahara, N. R. Payne, M. A. Horwitz, ibid. 144, 277 (1990).
6. P. Launois et al., Int. J. Lepr Other Mycobact. Dis. 60, 225 (1992).
7. S. Sturgill-Koszycki et al., Science 263, 678 (1994).
8. + serum, North American Biologicals, Miami, FL) or equine serum as described above or by batch mode. Protein eluted with HBSS, 0.1 M α-methyl mannoside was exchanged into phosphate-buffered saline (PBS) and used in the experiments at ∼0.15 mg/ml.
9. J. S. Schorey et al., data not shown.
10. 2-terminus of human C2a is shown in bold. Abbreviations for the amino acid residues: A, Ala; C, Cys; D, Asp; G, Gly; H, His; I, Ile; K, Lys; L, Leu; N, Asn; Q, GIn; R, Arg; S, Ser; and Y, Tyr.
11. G. Sitomer, R. M. Stroud, M. M. Mayer, Immunochemistry 3, 57 (1966); H. J. Muller-Eberhard, M. J. Polley, M. A. Calcott, J. Exp. Med. 125, 359 (1967).
12. G. Sitomer, R. M. Stroud, M. M. Mayer, Immunochemistry 3, 57 (1966); H. J. Muller-Eberhard, M. J. Polley, M. A. Calcott, J. Exp. Med. 125, 359 (1967).
13. R. M. Stroud, M. M. Mayer, J. A. Miller, A. T. McKenzie, Immunochemistry 3, 163 (1966); M. J. Polley and H. J. Muller-Eberhard, J. Exp. Med. 128, 533 (1968).
14. R. M. Stroud, M. M. Mayer, J. A. Miller, A. T. McKenzie, Immunochemistry 3, 163 (1966); M. J. Polley and H. J. Muller-Eberhard, J. Exp. Med. 128, 533 (1968).
15. To make the protein A-anti-C2, we incubated 0.05 ml of the rabbit polyclonal serum against human C2, which cross-reacts with equine C2, with 0.05 ml of packed protein A-Sepharose (Sigma) in 0.9 ml of PBS for 2 hours at 4°C. The protein A-Sepharose with coupled antibody was washed twice with PBS and resuspended in 0.1 ml of PBS. Approximately 0.2 mg of Con A-fractionated proteins from heat-treated equine serum or human serum (obtained from a mixed lymphocyte reaction) in PBS was incubated with protein A-Sepharose or protein A-Sepharose with bound anti-C2 for 3 hours at 4°C. The protein A was subsequently removed and the treated samples tested for the ability to support M. avium invasion of human monocyte-derived macrophages. No detectable C2 or C2 fragments were observed in the anti-C2-treated samples by protein immunoblot analysis with goat anti-C2 (human).
16. M. R. Wessels et al., Proc. Natl. Acad. Sci. U.S.A. 92, 11490 (1995).
17. R. W. Stokes, J. D. Haidl, W. A. Jefferies, D. P. Speert, J. Immunol. 151, 7067 (1993); L. S. Schlesinger, ibid. 150, 2920 (1993).
18. R. W. Stokes, J. D. Haidl, W. A. Jefferies, D. P. Speert, J. Immunol. 151, 7067 (1993); L. S. Schlesinger, ibid. 150, 2920 (1993).
19. F. S. Cole, W. J. Matthews Jr., J. T. Marino, D. J. Gash, H. R. Colten, ibid. 125, 1120 (1980); H. U. Schorlemmer, D. Bitter-Suermann, A. C. Allison, Immunology 32, 929 (1977) ; H. U. Schorlemmer and A. C. Allison, ibid. 31, 781 (1976).
20. F. S. Cole, W. J. Matthews Jr., J. T. Marino, D. J. Gash, H. R. Colten, ibid. 125, 1120 (1980); H. U. Schorlemmer, D. Bitter-Suermann, A. C. Allison, Immunology 32, 929 (1977) ; H. U. Schorlemmer and A. C. Allison, ibid. 31, 781 (1976).
21. F. S. Cole, W. J. Matthews Jr., J. T. Marino, D. J. Gash, H. R. Colten, ibid. 125, 1120 (1980); H. U. Schorlemmer, D. Bitter-Suermann, A. C. Allison, Immunology 32, 929 (1977) ; H. U. Schorlemmer and A. C. Allison, ibid. 31, 781 (1976).
22. J. Brostoff, L. Lenzini, P. Rottoli, L. Rottoli, Tubercle 62, 169 (1981); R. I. Carr et al., Clin. Exp. Immunol. 39, 562 (1980).
23. J. Brostoff, L. Lenzini, P. Rottoli, L. Rottoli, Tubercle 62, 169 (1981); R. I. Carr et al., Clin. Exp. Immunol. 39, 562 (1980).
24. K. S. S. Sai-Baba, K. D. Moudgil, R. C. Jain, L. M. Srivastava, Tubercule 71, 103 (1990).
25. I. H. Lepow, G. B. Naff, E. W. Todd, J. Pensky, C. F. Hinz, J. Exp. Med. 117, 983 (1963).
26. A. Zheleznyak and E. J. Brown, J. Biol. Chem. 267, 12042 (1992).
27. 2 in 0.2 ml of RPMI, 0.5% human serum albumin (infection media). The cells were washed with PBS, fixed with acetone/methanol (1:1), and stained for pathogenic mycobacteria with a TB Fluorescent Stain Kit O (Becton Dickinson, Cockney, MD). Macrophages infected with M. smegmatis, M. vaccae, and M. phlei were fixed in 2.5% glutaraldehyde and stained with acridine orange. The number of macrophages containing attached and internalized mycobacteria was scored visually with a Nikon Microphot-FX fluorescent microscope. The number of macrophages with associated mycobacteria per 100 cells is given as percent infected. For some experiments, the data are presented as the mean ± SD for 300 macrophages counted and represent variability within a given experimental chamber well. Defining the number of macrophages infected with organisms other then mycobacteria was done by visual inspection with a Zeiss Axioskop microscope.
28. 2+ with C1 and C4. After the final 2-hour incubation, EA were removed by centrifugation, and 0.1 ml of the supernatant was tested for the ability to support M. avium invasion of human monocyte-derived macrophages.
29. T. I. Roach, C. H. Barton, D. Chatterjee, J. M. Blackwell, J. Immunol. 150, 1886 (1993).
30. -/- mice were obtained through the eye orbital. The blood was allowed to clot for 30 min at 25°C and then 30 min at 4°C. The serum was cleared of clotted blood by centrifugation and immediately treated with a bovine serum albumin (BSA)-anti-BSA immune complex for 1 hour at 37°C. The immune complex was removed by centrifugation and the serum incubated at 56°C for 30 min to inactivate the complement pathways and stored at -70°C until needed.
31. S. D. Wright et al., Proc. Natl. Acad. Sci. U.S.A. 80, 5699 (1983).
32. H. D. Gresham, I. L. Graham, D. C. Anderson, E. J. Brown, J. Clin. Invest. 88, 588 (1991).
33. R. A. Hoffman, P. C. Kung, W. P. Hansen, G. Goldstein, Proc. Natl. Acad. Sci. U.S.A. 77, 4914 (1980).
34. E. Brown, L. Hooper, T. Ho, H. Gresham, J. Cell Biol. 111, 2785 (1990).
35. H. D. Gresham, J. L. Goodwin, P. M. Allen, D. C. Anderson, E. J. Brown, ibid. 108, 1935 (1989).
36. We thank C. Hammer (NIH) for polyclonal anti-C2 and D. Russell (Washington University) for the L. mexicana and L. monocytogenes. Supported in part by NIH grant AI33348. J.S.S. is an American Foundation for Urologic Disease-Dornier Medical System Research Scholar.